Advances in Drug Treatment for Osteoporosis
As China's population ages increasingly, osteoporosis has emerged as a severe public health concern.
August 15, 2025
by Xiaonisha
Research Progress on the Bioactivities and Pharmacological Mechanisms of Naringin
Naringin, also known as heteroside, citrus glycoside, and neohesperidin, has the chemical name of 4,5,7-trihydroxyflavanone-7-rhamnoside.
July 23, 2025
by Xiaomichong
osteolabs Publishes First Real-World Evidence Data from Close to 3, 000 OsteoTest Patient Samples
osteolabs GmbH announced the publication of real-world evidence data from close to 3,000 OsteoTest patient samples in the prestigious journal Bone.
August 16, 2024
by Biotech Newswire
Osteolabs to Present New Clinical Data from Over 2.400 OsteoTest Routine Samples at the WCO-IOF-ESCEO Congress
New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.
April 10, 2024
by PharmaSources
Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002
Transcenta Holding Limited announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002.
July 7, 2021
by prnasia
Drug doubles down on bone cancer, metastasis
Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.
June 24, 2021
by worldpharmanews
Osteoporosis drug may halve repeat hip replacement procedures: Study
Researchers from the University of Sheffield and Sheffield Teaching Hospitals found the osteoporosis drug, denosumab, could protect patients from osteolysis, reduce the need for re-operations, and reduce the health burden of this disease.
January 15, 2021
by expresspharma
Haoma Medica Completes First-in-Human Trial for Osteoporosis Treatment
Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
December 14, 2020
by americanpharmaceuticalreview
Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis
Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
November 27, 2020
by prnasia
Common osteoporosis treatments could reduce incidence of COVID-19
Osteoporosis treatments including denosumab, zoledronate and calcium could protect patients against COVID-19, researchers have said.
November 6, 2020
by europeanpharmaceuticalreview
One broken bone leads to another, warns IOF on World Osteoporosis Day
Today, the International Osteoporosis Foundation (IOF) calls for all adults to be alert to their risk factors for osteoporosis, a disease which can lead to a dangerous, life-threatening spiral of broken bones.
October 22, 2020
by prnasia
Using rafts to enhance bioavailability of ibandronate
Researchers have developed a novel tablet formulation of ibandronate which increases the oral bioavailability of the drug by releasing it from a hydrogel raft formed in the stomach.
October 16, 2020
by europeanpharmaceuticalreview